Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis

(2019) Ramy Gadalla et al.   BREAST CANCER RESEARCH AND TREATMENT

Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma

(2019) Saeed Daneshmandi et al.   Cancers

Dual blockade of CXCL12-CXCR4 and PD-1–PD-L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment

(2019) Yang Zeng et al.   FASEB JOURNAL

Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors

(2018) Elizabeth A. Kuczynski et al.   MOLECULAR CANCER THERAPEUTICS

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?

(2018) Carlos Rosales   Frontiers in Physiology

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

(2018) Soumaya Kouidhi et al.   Frontiers in Immunology

Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses

(2018) Rafael Cubas et al.   JOURNAL OF IMMUNOLOGY

Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms

(2018) Jinming Yang et al.   Cancer Immunology Research

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

(2018) Han Yao et al.   Frontiers in Immunology

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

(2018) Chloé Grasselly et al.   Frontiers in Immunology

Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1

(2017) Hui Li et al.   HEPATOLOGY

Structure–Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist

(2017) Salvatore Di Maro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer

(2017) Sara Santagata et al.   Oncotarget

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade

(2017) Dirk Zboralski et al.   Cancer Immunology Research

A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors

(2017) Sara Santagata et al.   Scientific Reports

A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion

(2016) Raffaela Fontanella et al.   CANCER LETTERS

Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model

(2016) Laura Mercurio et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists

(2016) Salvatore Di Maro et al.   JOURNAL OF MEDICINAL CHEMISTRY

CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis

(2016) Caterina Ieranò et al.   Nanoscale

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

(2016) B. Homet Moreno et al.   Cancer Immunology Research

A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

(2015) Shin Foong Ngiow et al.   CANCER RESEARCH

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment

(2015) S. Scala   CLINICAL CANCER RESEARCH

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

(2015) Yunching Chen et al.   HEPATOLOGY

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Downregulation of UHRF1 promotes EMT via inducing CXCR4 in human cancer cells

(2014) YI-DEUN JUNG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin

(2014) Ling Mei et al.   JOURNAL OF CONTROLLED RELEASE

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

(2014) S. Chen et al.   Cancer Immunology Research

Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases

(2013) Luigi Portella et al.   PLoS One

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms

(2012) S. Demoulin et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer

(2011) E. Righi et al.   CANCER RESEARCH

COX-2 and Prostaglandin EP3/EP4 Signaling Regulate the Tumor Stromal Proangiogenic Microenvironment via CXCL12-CXCR4 Chemokine Systems

(2010) Hiroshi Katoh et al.   AMERICAN JOURNAL OF PATHOLOGY

Statistical Inference for Tumor Growth InhibitionT/CRatio

(2010) Jianrong Wu   Journal of Biopharmaceutical Statistics

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA